Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
13vPnC Formulations vs 23vPS in Elderly
NCT00269672Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2005
- Primary completion
- Feb 2007
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 2, randomised, open-label trial of Prevnar 13 in pneumococcal disease (3 arms), sponsored by Pfizer. Primary endpoint: Immunogenicity comparison of 13vPnC with and without AlPO4. Started Sep 2005; status: completed.
02
Drugs
Prevnar 13
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT00269672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00269672.